Department of Gastroenterology and Hepatology, Tokyo Medical University, 6-7-1 Nishishinjuku Shinjuku-ku, Tokyo 160-0023, Japan.
Department of Gastrointestinal and Pediatric Surgery, Tokyo Medical University, 6-7-1 Nishishinjuku Shinjuku-ku, Tokyo 160-0023, Japan.
Curr Oncol. 2021 Nov 20;28(6):4845-4861. doi: 10.3390/curroncol28060409.
High-intensity focused ultrasound (HIFU) is a novel advanced therapy for unresectable pancreatic cancer (PC). HIFU therapy with chemotherapy is being promoted as a novel method to control local advancement by tumor ablation. We evaluated the therapeutic effects of HIFU therapy in locally advanced and metastatic PC. PC patients were treated with HIFU as an optional local therapy and systemic chemotherapy. The FEP-BY02 (Yuande Bio-Medical Engineering) HIFU device was used under ultrasound guidance. Of 176 PC patients, 89 cases were Stage III and 87 were Stage IV. The rate of complete tumor ablation was 90.3%, while that of symptom relief was 66.7%. The effectiveness on the primary lesions were as follows: complete response (CR): n = 0, partial response (PR): n = 21, stable disease (SD): n = 106, and progressive disease (PD): n = 49; the primary disease control rate was 72.2%. Eight patients underwent surgery. The median survival time (MST) after diagnosis for HIFU with chemotherapy compared to chemotherapy alone (100 patients in our hospital) was 648 vs. 288 days ( < 0.001). Compared with chemotherapy alone, the combination of HIFU therapy and chemotherapy demonstrated significant prolongation of prognosis. This study suggests that HIFU therapy has the potential to be a novel combination therapy for unresectable PC.
高强度聚焦超声（HIFU）是一种治疗不可切除胰腺癌（PC）的新型先进疗法。HIFU 联合化疗被作为一种通过肿瘤消融控制局部进展的新方法而被推广。我们评估了 HIFU 治疗在局部晚期和转移性 PC 中的治疗效果。PC 患者接受 HIFU 作为可选的局部治疗和全身化疗。使用 FEP-BY02（元德生物医学工程）HIFU 设备在超声引导下进行治疗。在 176 例 PC 患者中，89 例为 III 期，87 例为 IV 期。完全肿瘤消融率为 90.3%，而症状缓解率为 66.7%。对原发病灶的疗效如下：完全缓解（CR）：n = 0，部分缓解（PR）：n = 21，稳定疾病（SD）：n = 106，进展疾病（PD）：n = 49；原发病灶控制率为 72.2%。8 例患者接受了手术。HIFU 联合化疗与单纯化疗相比（我院 100 例患者）的中位生存时间（MST）分别为 648 天和 288 天（<0.001）。与单纯化疗相比，HIFU 联合化疗治疗显著延长了预后。本研究表明，HIFU 治疗有可能成为不可切除 PC 的一种新型联合治疗方法。
